Browse > Article

Treatment for HIV-Infected Patients to Induce Long-Term Non-Progressor with Constant Drug Dosage  

Kim Jinyoung (한양대 공대 전자전기컴퓨터공학부)
Kim Won Hee ((주)삼성전자 TN총괄)
Ko Ji Hyun (McGill University 의대 신경과학부)
Chung Han Byul (한양대 공대 전기공학과)
Chung Chung Choo (한양대 공대 전자전기컴퓨터공학부)
Publication Information
The Transactions of the Korean Institute of Electrical Engineers D / v.54, no.4, 2005 , pp. 259-266 More about this Journal
Abstract
This paper presents a therapy that uses a constant drug dosage for leading HIV-infected patient to LTNP (Long-Term Non-Progressor). Based on analysis of CTLp (Cytotoxic T Lymphocyte precursor) concentration at equilibrium point and its bifurcation, we found the therapy with a drug whose efficacy is less than a certain level brings higher CTLp concentration at the equilibrium point. We observed a treatment with constant drug dosage whose efficacy is less than full treatment may lead HIV-infected patient to LTNP. It turns out that the treatment whose efficacy is less than full treatment is better in the point of performance on controllability.
Keywords
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 M. Clerici, E. Seminari, F. Suter, et al, 'Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy treated and antiretroviral-napatient with undetectable viraemia,' AIDS, vol. 14, pp. 109-116, 2000   DOI
2 J. Gerstoft, O. Kirk, N. Obel, C. Pedersen, L. Mathiesen, H. Nielsen, TL. Katzenstein, JD. Lundgren, 'Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir,' AIDS, vol. 17, pp. 2045-2052, 2003   DOI
3 M. A. Nowak and R. M. May,'Virus Dynamics: Mathematical principles of immunology and virology,' Oxford University Press, 2000
4 R. A. Arnaout, M. A. Martin, and D. Wodarz, 'HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?,' In Proceedings of the Royal Society of London. series Biological sciences, vol. 267, pp. 1347-1354, 2000
5 H. Shim, H. Chang, and J. Seo, 'Non-vanishing basin of attraction with respect to a parametric variation and center manifold,' In proceedings of IEEE Conference on Decision and Control, pp. 2984-2989, 2004
6 A. M. Jeffrey, X. Xia, and I. K. Craig, 'When to inititate HIV therapy: a control theoretic approach,' IEEE Trans. On Biomedical Engineering, vol. 50, no 11, pp. 1213-1220, Nov. 2003   DOI   ScienceOn
7 S. Kubiak, H. Lehr, R. Levy, T. Moeller, A. Parker and E. Swim, 'Control of HIV infection through structured treatment interruptions with recommendations for experimental protocol,' CRSC Technical Report (CRSC-TR01-27) pp. 1-20, 2001. (Also at http://www.math.montana.edu/-parker.)
8 'Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,' aidsinfo. nih.gov, March 23, 2004. [Online] Available: http://www.aidsinfo.nih.gov/guidlines/adult/AA_032304.html
9 H. Chang, H. Shim, and J. Seo, 'Control of immune response of HIV infection model by gradual reduction of drug dose,' In Proc. of Conference on Decision and Control, pp. 1048-1054, 2004
10 J. H. Ko, W. H. Kim, and C. C. Chung, 'Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability,' In Proc. of IEEE Conference on Decision and Control, pp. 1055-1060, 2004
11 R. Zurakowski and A. R. Teel, 'Enhancing immune response to HIV infection using MPC-based treatment scheduling,' In proceedings of American Control Conference, pp. 1182-1187, 2003   DOI
12 허영희, 고지현, 김진영, 정정주, 남상원, 심형보, 'HIV 동역학과 최적 제어를 이용한 약물 치료에 관한 고찰,' Journal of Control, Automation and Systems Engineering, vol. 10, No.6, pp. 475-486, June 2004   과학기술학회마을   DOI
13 'Treatment interruptions,' factsheets, AIDS.org, April, 2003. [Online] Available: http://www.aids.org/factSheets/406-Treatment- Interruptions.html
14 'What is AIDS,' factsheets, AIDS.org, November 22, 2003. [Online] Available: http://www.aids.org/factSheets/101-What-is-AIDS.html
15 D. Wodarz, 'Helper-dependent vs. helper -independent CTL responses in HIV infection: implications for drug therapy and resistance,' J. Theor. Biol., vol. 213, pp. 447-459, August 2001   DOI   ScienceOn
16 H. Shim, S. J. Han, C. C. Chung, S. W. Nam and J. H. Seo, 'Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control,' International Journal of Control, Automation, and Systems, vol. 1. no. 3, pp. 282-288, 2003
17 D. Wodarz and M. A. Nowak, 'Specific therapy regimes could lead to long-term immunological control of HIV,' PNAS, vol. 96, pp. 14464-14469, December 1999   DOI
18 D. Douek, J. Brenchley, M. Betts, D. Ambrozak, B. Hill, Y. Okamoto, J. Casazza, J. Kuruppu, K. Kunstman, S. Wollnsky, Z. Grossman, M. Dybul, A. Oxenlus, D. Price, M. Conners, and R. Koup, 'HIV preferentially infects HIV-specific CD4+ T cells,' Nature, vol. 417, pp. 95-98, 2002   DOI   ScienceOn
19 C. A. Janeway, P. Travers, M. Walport, and M. Shlomchik, 'Immunobiology,' Garland Churchill Livingstone, 2001
20 S. Bonhoeffer, M. Rembiszewski, G. M. Ortiz, D. F. Nixon, 'Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection,' AIDS, vol. 14, pp. 2313-2322, 2000   DOI   ScienceOn